skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Caracemide (Code C1037)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Caracemide

Definition: An agent derived from acetohydroxamic acid with potential antineoplastic activity. Caracemide inhibits ribonuclease reductase, resulting in decreased DNA synthesis and tumor growth; it also inhibits acetylcholinesterase. In vivo, caracemide contributes to the formation of the neurotoxin methyl isocyanate; this effect, along with the agent's acetylcholinesterase activity, may be responsible for the severe central nervous system toxicity observed in clinical trials. (NCI04)

Label: Caracemide

NCI Thesaurus Code: C1037 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C0054633  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Acetamide, N-[(methylamino)carbonyl]-N-[[(methylamino)carbonyl]oxy]- (9CI)
Acetamide, N-[(Methylamino)carbonyl]-N-[[(methylamino)carbonyl]oxy]-(9CI)

External Source Codes: 
CAS Registry Number 81424-67-1 (see NLM ChemIDplus info)
FDA UNII Code H74F6J185A
NSC Code 253272 (see NCI DTP info)
PDQ Closed Trial Search ID 39751
PDQ Open Trial Search ID 39751 (check for NCI PDQ open clinical trial info)
UMLS CUI C0054633

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C6H11N3O4
code C1037
Contributing_Source FDA
Legacy_Concept_Name Caracemide
Semantic_Type Organic Chemical
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom